NRX Pharma rises on positive FDA feedback for bipolar disorder drug

NRX Pharmaceuticals

19/01/2023 12:39

** Shares of NRX Pharmaceuticals Inc  NRXP.O  rise 6.4% to
$1.33 premarket
    ** Drug developer says it received positive feedback from
FDA for development of its experimental drug to treat bipolar
depression and suicidal tendencies 
    ** Co, FDA are in agreement regarding NRXP's proposed
manufacturing plan for the drug, NRX-101
    ** NRX-101 is an oral drug which targets the brain's NMDA
receptor responsible for memory formation     
    ** NRXP fell ~69% in the past 12 months 
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))